B+
Bull case
25%
Probability
Target price
$56.00
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
SNY
SanofiANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$49.00
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$37.00
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-05
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+78.0
Score
AI commentary
Primary-company news tone is positive after strong Q2 growth, upgraded guidance, and the MenQuadfi approval, but the evidence packet lacks social coverage, options data, short interest, employee sentiment, and verified post-print analyst revisions. The $42.68 August 4 anchor indicates that the positive earnings narrative is not fully reflected versus the supplied $50.60 median target, but the high uncertainty score and pipeline reset argue for monitoring rather than aggressive conviction.
RankAlpha Sentiment Codex - 2026-08-05
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-30eventQ2 growth and 2026 guidance upgradeMedium impact
Sanofi reported Q2 sales growth of 17.8% at constant exchange rates, Dupixent growth of 37.6%, business EPS growth of 33.3%, and upgraded 2026 sales guidance to around 10% growth with business EPS growing slightly faster [#PR-EARNINGS-2026-07-30].
2026-08-04eventMenQuadfi EU infant indication approvalMedium impact
The European Commission approved MenQuadfi for infants from six weeks of age, expanding the addressable pediatric indication in the EU [#PR-2026-08-04].
2026-09-30catalystSecond-half normalization and pipeline reset digestionMedium impact
Sanofi expects growth to normalize in the second half and has discontinued amlitelimab development in atopic dermatitis plus two other clinical programs, creating execution and sentiment risk [#PR-EARNINGS-2026-07-30] [#PR-2026-07-24].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-05 • Updated nightlySource: Internal modelMethodology